https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 25 Aug 2021 11:22:50 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/rg90oiouawo-a-look-into-the-future-car-t-and-bispecifics-in-myeloma/ Fri, 26 Feb 2021 14:08:23 +0000 http://13.40.107.223/video/rg90oiouawo-a-look-into-the-future-car-t-and-bispecifics-in-myeloma/ Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the future of CAR T-cell therapy and bispecific monoclonal antibodies in multiple myeloma. When approved, the optimal use for these therapies would be in triple-refractory myeloma patients, but these strategies will move into earlier lines of treatment in the future. Currently, ongoing clinical trials are evaluating the role of bispecifics and CAR T-cells following one/three prior lines of therapy. While other trials are evaluating the safety and efficacy of CAR T-cells in the front-line setting in patients with high-risk myeloma. Dr Mateos highlights different strategies, currently being investigated in preliminary clinical trials, to improve the efficacy of BCMA CAR T-cells. In the bispecific antibody field, new targets beyond BCMA are being investigated, including GPRC5D-directed bispecifics, as well as novel combinations of immune and targeted therapies. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/nlbyumq8hty-clinical-advances-with-car-ts-and-bispecifics-in-rr-myeloma/ Fri, 26 Feb 2021 14:08:23 +0000 http://13.40.107.223/video/nlbyumq8hty-clinical-advances-with-car-ts-and-bispecifics-in-rr-myeloma/ Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the recent clinical advances with CAR T-cells and bispecifics in relapsed/refractory (R/R) multiple myeloma. Over the past decade, new treatments have transformed survival outcomes of myeloma. However, patients with myeloma refractory to the therapies that currently comprise the hematologic standard of care, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies, have limited treatment options. It is expected that additional agents will be available for triple-refractory disease soon. Dr Mateos highlights idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), both BCMA-targeting CAR T-cells. Various bispecific monoclonal antibodies targeting BCMA are currently in development, with promising results. This interview took place during the 3rd European CAR T-cell Meeting.

]]>